Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma

Loading news article.

Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma | WAPE

Regeneron Announced Sunday At ESMO, Updated Phase 3 C-POST Data Showing Libtayo Reduced Risk Of Death By 37% Vs. Placebo At 44-Month Follow-Up In High-Risk Cutaneous Squamous Cell Carcinoma

Article summary

Related companies

Comments —